40 years, 6 exits - a CEO addict

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adam Sherlock, CEO at Qinecsa.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering:

• How he developed his professional CEO skills over the years to complement is entrepreneurial spirit


• The combination of micro and macro factors that help determine when the right time is to go to market, and sell


• The importance of your gut instinct when assessing M&A targets... and painting a picture of why the world is a better place when together


• Several attempts at failing to retire... and being tempted back into another pharma services CEO role


• How R&D services will be impacted by AI, and why we all need to be eating our own lunch

Adam is a serial entrepreneur and executive leader with nearly 40 years of experience in the international life sciences industry, particularly in bio/pharma, IVD, and medical device sectors. A scientist by training, he has led successful growth and M&A efforts, creating exceptional value in four private equity-backed businesses over the past decade. 

Adam is also a sought-after NED, Chair, and independent advisor. Currently, he serves as CEO of Qinecsa, a global provider of pharmacovigilance technology and services.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.